Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Finding True North in Drug Development
Regeneron’s Andres Sirulnik reflects on the experiences that took him from treating leukemia patients to developing medicines – and why following the science still means putting patients first
Andres Sirulnik’s early family experience with leukemia helped shape his ambition to become a hematologist-oncologist.
2
After training in Argentina and England, Sirulnik learned to make monoclonal antibodies at Cambridge’s MRC Laboratory of Molecular Biology with César Milstein.
3
Sirulnik moved from patient care and academia to industry to pursue translational research and reach more patients through drug development.
4
Milstein taught Sirulnik to use precise language when describing data, a lesson that informs his science-driven approach to development.
5
Sirulnik says drug development should follow the science and address relevant problems for patients, clinicians, and the organization, while adapting to external hurdles.